Item 8.01. Other Events. On December 1, 2025, Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the “ Company”), obtained approval of its stockholders holding a majority of the voting power of the Company’s outstanding capital stock, by written consent (the “ Written Consent”), to effect a reverse stock split of its issued and outstanding shares of common stock at a ratio of one-for-ten (1-for-10) (the “ Reverse Stock Split”) and to amend the Company’s Amended and Restated Certificate of Incorporation (the “ Charter Amendment”) accordingly. In connection with the Written Consent, the Company filed and mailed an information statement (the “ Information Statement”) to its stockholders pursuant to Rule 14c-2 under the Securities Exchange Act of 1943, as amended. The Reverse Stock Split will not become effective until at least 20 calendar days after the mailing of the definitive Information Statement (the “Waiting Period”).

Item 9.01 Financial Statements and Exhibits. (d) Exhibits.